Gabather AB (GABA) AI Stock Analysis

• Market Cap: kr13.77M
• Dividend Yield: N/A
• Average Volume (3M): 488.51K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.31
• Revenue Growth: N/A
• EPS Growth: 72.30%
• Country: SE
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.00
• Shares Outstanding: 491,634,160
• 10 Day Avg. Volume: 541,248
• 30 Day Avg. Volume: 488,507
• PEG Ratio: 0.02
• Price to Book (P/B): -1.98
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.49
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: kr0.03 ▲(0.00% Upside)

The score is primarily constrained by weak financial performance (no revenue, persistent losses, negative equity, and ongoing cash burn). Technicals add further pressure with a weak long-term trend and negative MACD, while valuation metrics are unfavorable due to loss-making status and no dividend support.

Positive Factors

Debt-Free Status

Having no debt provides Gabather AB with greater financial flexibility and reduces the risk of financial distress, allowing the company to focus on strategic initiatives without the burden of interest obligations.

Improved Cash Burn

The reduction in cash burn indicates better cost management, which can extend the company's runway and provide more time to achieve operational milestones or secure additional funding.

Cost Control

Effective cost control measures have reduced losses, which could lead to improved financial health over time and demonstrate management's ability to adapt to challenging conditions.

Negative Factors

Negative Shareholders' Equity

Negative equity suggests that liabilities exceed assets, which can limit the company's ability to raise capital and poses a risk to financial stability and investor confidence.

No Revenue Generation

The absence of revenue generation indicates that Gabather AB is still in a pre-commercial phase, which may delay profitability and increase reliance on external funding to sustain operations.

Ongoing Cash Outflows

Continued negative cash flow highlights the company's dependence on external financing, which could be challenging to secure and may dilute existing shareholders if equity is issued.

Gabather AB Business Overview & Revenue Model

Company Description

Gabather AB (publ) develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company was incorporated in 2014 and is based in Södertälje Sweden.

How the Company Makes Money

Gabather AB generates revenue primarily through the development and potential commercialization of its pharmaceutical candidates. The company's business model involves advancing its drug candidates through clinical trials with the aim of obtaining regulatory approval. Success in these trials can lead to partnerships with larger pharmaceutical companies, licensing agreements, or direct sales of approved therapies. Key revenue streams include milestone payments and royalties from partnerships, as well as potential sales revenue from successful drug commercialization. Gabather may also engage in research collaborations that contribute to its earnings.

Gabather AB Financial Statement Overview

Summary

Financials indicate a highly challenged/pre-commercial profile: no revenue reported, recurring net losses, and ongoing negative operating/free cash flow. While cash burn improved in 2024 and there is no reported debt, negative shareholders’ equity and a sharp contraction in total assets elevate funding and continuity risk.

Income Statement

The company reports no revenue across the period provided, while losses are persistent every year (net loss of ~SEK 7.8m in 2024 vs ~SEK 9.4m in 2023, and materially larger losses in earlier years). The main positive is that losses have narrowed from the 2020–2021 peak, suggesting some cost control, but profitability remains deeply negative with no visible top-line traction in the data.

Balance Sheet

Reported debt is zero, which reduces financial-risk from leverage. However, the balance sheet has weakened substantially: shareholders’ equity fell from positive levels in prior years to negative in 2024 (about -SEK 4.2m), indicating accumulated losses have overtaken the capital base. Total assets have also contracted sharply over time (from ~SEK 46.1m in 2019 to ~SEK 1.8m in 2024), which limits financial flexibility.

Cash Flow

Cash generation is consistently negative, with operating and free cash flow both at about -SEK 3.3m in 2024, following much heavier cash burn in 2023 (-SEK 11.6m). The improvement in 2024 is a near-term positive, but free cash flow growth is still negative year over year and the business remains reliant on external funding to sustain operations given ongoing cash outflows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-4.12M	0.00	37.00K	-8.55M	-16.99M	-14.66M
Net Income	-4.46M	-7.75M	-9.44M	-8.54M	-17.00M	-14.95M
Balance Sheet
Total Assets	3.50M	1.83M	7.36M	6.75M	15.39M	32.16M
Cash, Cash Equivalents and Short-Term Investments	3.00M	878.00K	1.11M	6.27M	14.85M	30.92M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	4.48M	6.01M	6.88M	3.31M	4.43M	3.31M
Stockholders Equity	-983.00K	-4.17M	486.00K	3.44M	10.96M	27.91M
Cash Flow
Free Cash Flow	-5.16M	-3.33M	-11.64M	-9.60M	-16.12M	-13.98M
Operating Cash Flow	-5.16M	-3.33M	-11.64M	-9.60M	-16.12M	-13.69M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	-289.00K
Financing Cash Flow	7.18M	3.09M	6.49M	1.02M	46.00K	0.00

Gabather AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.03
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GABA, the sentiment is Neutral. The current price of 0.03 is above the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and below the 200-day MA of 0.04, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 53.31 is Neutral, neither overbought nor oversold. The STOCH value of 73.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:GABA.

Gabather AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KLAR	49 Neutral	kr287.79M	-3.97	-530.21%	―	―	17.42%
NANEXA	48 Neutral	kr579.96M	-14.08	-48.65%	―	-60.33%	58.04%
ERMA	43 Neutral	kr114.87M	-1.29	―	―	―	―
ALZCUR	42 Neutral	kr221.21M	-4.76	-90.66%	―	―	15.74%
GABA	41 Neutral	kr13.77M	-0.74	―	―	―	72.30%